Samsung Biologics said in a public filing on Thursday that it signed a contract manufacturing organization (CMO) deal with Pfizer worth $183 million (241 billion won), which is equivalent to 15.37 percent of total sales in 2021.

The contract period is from February 20, 2023, to December 31, 2029. However, like other contracts in the past, the company kept quiet about which product and how much it will manufacture, citing contractual reasons.

Samsung Biologics also explained that the end date of the contract period is subject to change according to changes in contract conditions, such as production schedules.

It is the first time that Samsung Biologics officially admitted its deal with Pfizer through a public disclosure.

So far, Samsung Biologics has signed CDMO contracts with seven out of the top 10 multinational pharmaceutical companies based on total sales in 2021, according to data from Globaldata, a market research firm. 

The Pfizer contract is the second CMO contract signed by Samsung Biologics this year.

In February, the company signed a $27 million CDMO agreement with GSK in February.

Including the GSK contract, the company has already secured CMO contracts worth $209 million in the first quarter of this year alone.